Clinical Trial Search

Primary: Trough Forced Expiratory Volume in One Second (FEV1) After 7 Days of Treatment — 2.84; 2.83; 2.80; 2.64 Liters

Primary: Complete Wound Closure — 14.8; 14.9 days

Primary: Determine the Predictive Value of Cardiolite® Rest and Stress MPI to Define Pediatric Populations With Kawasaki Disease at High and Low Risk of Developing Cardiac…

Primary: Quantitative Assessment of Air Embolism to the Brain After Completion of Open Left Heart Surgery — 49; 46 Air microemboli

Primary: Effective Bleeding Control Defined as no Additional Haemostatic Medication (Other Than Trial Product) Given — 22; 16; 318; 211 bleeding episodes

Primary: Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population — 1; 1; 1; 2 participants

Primary: Number of Pain Free Headaches at 2 and 24 Hours Post-Dose — 3218; 5236; 3048 Number of headaches

Primary: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1 — 0; 9 Participants

Primary: Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains — 20.57; 19.02; 366.04; 110.44 Titer

Primary: FEV1 — 0.007; 0.011 L

Primary: Cumulative Probability of Participants With Testosterone at Castrate Level <= 0.5 ng/mL From Day 28 to Day 168 — 97.2 Percentage of participants

Primary: Proportion of Patients Free of Transfusion at 4 Months — 0.459; 0.714 Proportion of patients

Primary: Number of Seroconverted Subjects for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Cervarix 1 Group and…

Primary: Objective Tumor Response Through Week 16 — 6 participants

Primary: Leakage (Percentage of All Baseplates With Leakage) — 34; 35 percentage baseplates with leakage